Genes (Jun 2022)

Heterozygous <i>NPR2</i> Variants in Idiopathic Short Stature

  • Lana Stavber,
  • Maria Joao Gaia,
  • Tinka Hovnik,
  • Barbara Jenko Bizjan,
  • Maruša Debeljak,
  • Jernej Kovač,
  • Jasna Šuput Omladič,
  • Tadej Battelino,
  • Primož Kotnik,
  • Klemen Dovč

DOI
https://doi.org/10.3390/genes13061065
Journal volume & issue
Vol. 13, no. 6
p. 1065

Abstract

Read online

Heterozygous variants in the NPR2 gene, which encodes the B-type natriuretic peptide receptor (NPR-B), a regulator of skeletal growth, were reported in 2–6% cases of idiopathic short stature (ISS). Using next-generation sequencing (NGS), we aimed to assess the frequency of NPR2 variants in our study cohort consisting of 150 children and adolescents with ISS, describe the NPR2 phenotypic spectrum with a growth pattern including birth data, and study the response to growth hormone (GH) treatment. A total of ten heterozygous pathogenic/likely pathogenic NPR2 variants and two heterozygous NPR2 variants of uncertain significance were detected in twelve participants (frequency of causal variants: 10/150, 6.7%). During follow-up, the NPR2 individuals presented with a growth pattern varying from low–normal to significant short stature. A clinically relevant increase in BMI (a mean gain in the BMI SDS of +1.41), a characteristic previously not reported in NPR2 individuals, was observed. In total, 8.8% participants born small for their gestational age (SGA) carried the NPR2 causal variant. The response to GH treatment was variable (SDS height gain ranging from −0.01 to +0.74). According to the results, NPR2 variants present a frequent cause of ISS and familial short stature. Phenotyping variability in growth patterns and variable responses to GH treatment should be considered.

Keywords